What is the role of systemic corticosteroids in the management of chemotherapy‑induced colitis?

Role of Systemic Corticosteroids in Chemotherapy-Induced Colitis

Systemic corticosteroids are the first-line treatment for grade ≥2 chemotherapy-induced colitis (specifically immune checkpoint inhibitor-induced colitis), starting at 1-2 mg/kg/day prednisone equivalent, with escalation to biologics (infliximab or vedolizumab) if no improvement occurs within 72 hours or for high-risk endoscopic features. 1, 2

Graded Approach to Corticosteroid Use

Grade 1 Colitis (≤3 additional stools/day)

• Continue immunotherapy or hold temporarily
• Corticosteroids are NOT indicated
• Monitor closely every 3 days until stabilized 1

Grade 2 Colitis (4-6 additional stools/day)

• Hold immunotherapy immediately
• Start prednisone 1 mg/kg/day (or equivalent) unless diarrhea is transient 1
• If no improvement within 72 hours, this represents steroid-refractory disease requiring escalation 1
• Add infliximab or vedolizumab for:
  • No grade reduction after 72 hours of steroids
  • High-risk endoscopic features on initial colonoscopy
  • Steroid-dependent cases 1, 2
• Taper steroids over 4-6 weeks once symptoms improve to grade ≤1 1

Grade 3-4 Colitis (≥7 additional stools/day or life-threatening)

• Hospitalize for severe cases with dehydration or electrolyte imbalance 1
• Start IV methylprednisolone 1-2 mg/kg/day 1, 2
• Consider early introduction of biologics (within 10 days of onset) in addition to steroids, especially with:
  • High-risk endoscopic features
  • Inadequate response after 3 days of steroids 1, 2
• Early biologic introduction reduces symptom duration and improves steroid taper success 2

Critical Predictors of Steroid Failure

Recent evidence identifies patients at higher risk for steroid-refractory disease who may benefit from earlier biologic escalation:

• Combination ICI therapy (anti-CTLA-4 + anti-PD-1/PD-L1) predicts steroid refractoriness and requires more aggressive management 3
• Elevated serum IL-6 levels at colitis onset independently predict steroid-refractory disease 4
• Ulcerative lesions on endoscopy and fever at presentation are associated with steroid failure 4

Endoscopic Evaluation

Colonoscopy with biopsies is highly recommended for grade ≥2 colitis to:

• Stratify patients for early biologic treatment based on endoscopic severity 1
• Detect microscopic colitis even when endoscopy appears normal (88% of cases show histological inflammation despite normal endoscopy) 3
• Assess for endoscopic remission before ICI rechallenge 1

Duration and Tapering

• Taper corticosteroids over 4-6 weeks after improvement to grade ≤1 1, 2
• Shorter tapers may be considered in patients also treated with biologics 1
• Fecal calprotectin ≤116 mg/g may serve as a surrogate for endoscopic and histologic remission before completing taper 1

Common Pitfalls to Avoid

1. Do not delay biologic therapy in steroid-refractory cases—waiting beyond 72 hours without improvement prolongs symptoms and increases complications 1, 2
2. Do not use loperamide until infection is ruled out and only for diarrhea without colitis symptoms 1
3. Do not restart CTLA-4 inhibitors after grade 3-4 colitis; consider permanent discontinuation 1, 2
4. Do not rely solely on clinical symptoms—endoscopic remission is a better predictor of cure than clinical remission alone 2

Biologic Selection

When escalating beyond steroids:

• Infliximab: Anti-TNF-α antibody, well-established for steroid-refractory cases 2
• Vedolizumab: Gut-selective integrin antagonist that may theoretically preserve systemic antitumor immunity 2
• ≥3 doses of either biologic plus achieving endoscopic/histologic remission reduces relapse risk 2
• Introduce within 10 days of colitis onset for optimal outcomes 2

ICI Rechallenge Considerations

• PD-1/PD-L1 agents have lower flare-up risk upon rechallenge compared to CTLA-4 inhibitors 1
• Rechallenge only after steroid taper completion and achieving endoscopic/histologic remission 1
• Recent data shows 17.4% relapse rate with rechallenge, suggesting feasibility in selected patients 3

Note: The evidence provided focuses specifically on immune checkpoint inhibitor-induced colitis rather than traditional chemotherapy-induced colitis. The corticosteroid approach outlined above applies to ICI-induced colitis, which represents the most common and well-studied form of immunotherapy-related colitis requiring systematic corticosteroid management.